HeyJaredMiriam E. Tucker
- Indexed articles, last 90 days
- 30
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 8, 2026
Latest articles
Orforglipron Noninferior for CV Outcomes in T2D (opens the original)
Read excerpt
MILAN — The once-daily nonpeptide small molecule GLP-1 receptor agonist orforglipron (Foundayo, Eli Lilly) was noninferior to insulin glargine for cardiovascular (CV) outcomes in people with type 2 diabetes (T2D) at increased CV risk, according to results from a phase 3 trial. It also "showed clinically relevant improvements in glycemia and bodyweight," said study investigator Klara Klein, MD, PhD, assistant professor in the Division of Endocrinology and Metabolism at the University of North Car
Retatrutide Yields Significant Weight Loss in T2D (opens the original)
Read excerpt
MILAN — The investigational triple hormonal agonist retatrutide produced significant weight loss along with glycemic and cardiovascular improvements in adults with type 2 diabetes (T2D) and obesity, according to new results from Eli Lilly's phase 3 TRIUMPH-2 study. "We've seen in multiple studies, including those with bariatric surgery, that it's harder for people with type 2 diabetes to lose weight, even with the highest doses of GLP-1 or the dual GIP/GLP-1 agonist tirzepatide," said study co-a
GIP/GLP-1 Ups Beta-Cell Function, Insulin Sensitivity in T2D (opens the original)
Read excerpt
MILAN — Tirzepatide (Mounjaro, Eli Lilly) improved markers of beta-cell function and insulin sensitivity in people with recent-onset type 2 diabetes (T2D), a new prespecified analysis of SURPASS-EARLY showed. These findings could explain the superior glycemic control seen with tirzepatide compared with intensified conventional care (ICC) seen during the first 2 years of the trial, said Steven Kahn, MB ChB, professor of medicine and director of the University of Washington Diabetes Research Cente
Type 1 Diabetes Overall, Type 2 Diabetes in Kids on the Rise (opens the original)
Read excerpt
MILAN — Rates of both type 1 diabetes (T1D) and type 2 diabetes (T2D) are rising among youth in the United States, while the global T1D burden is expected to skyrocket in the coming years, data from two epidemiologic studies suggest. Results of both studies are being presented separately here at the European Association for the Study of Diabetes (EASD) 2026 Annual Meeting. The incidence of T1D in those younger than 20 years has been rising since 2014, while T2D in that age group has been increas
ADA Issues Primary Care Guidance on Diabetes Technology Use (opens the original)
Read excerpt
The American Diabetes Association (ADA) has released a scientific statement with recommendations for the use of diabetes technology in primary care in order to address challenges in awareness of, access to, and adoption of such technology in primary care settings. “Most diabetes care is delivered in primary care, yet diabetes technologies remain inconsistently integrated. Workforce, training, time, data infrastructure, and insurance barriers contribute to inequitable access and adoption,” wrote
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.